These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9635566)

  • 21. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
    Piehler J; Schreiber G
    J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
    Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-viral proteins: from interferon alpha to its receptor].
    Chieux V; Hober D; Chehadeh W; Wattr P
    Ann Biol Clin (Paris); 1999 May; 57(3):283-90. PubMed ID: 10377478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.
    Dupuis S; Jouanguy E; Al-Hajjar S; Fieschi C; Al-Mohsen IZ; Al-Jumaah S; Yang K; Chapgier A; Eidenschenk C; Eid P; Al Ghonaium A; Tufenkeji H; Frayha H; Al-Gazlan S; Al-Rayes H; Schreiber RD; Gresser I; Casanova JL
    Nat Genet; 2003 Mar; 33(3):388-91. PubMed ID: 12590259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
    Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
    Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The interferon system. A review of biological principles and clinical uses].
    Schneider FJ
    Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrin alpha 11 is a novel type I interferon stimulated gene.
    Leomil Coelho LF; Mota BE; Sales PC; Marques JT; de Oliveira JG; Bonjardim CA; Peregrino Ferreira PC; Kroon EG
    Cytokine; 2006 Mar; 33(6):352-61. PubMed ID: 16697656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic role of beta-interferons in multiple sclerosis.
    Javed A; Reder AT
    Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection.
    Nguyen KB; Watford WT; Salomon R; Hofmann SR; Pien GC; Morinobu A; Gadina M; O'Shea JJ; Biron CA
    Science; 2002 Sep; 297(5589):2063-6. PubMed ID: 12242445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors.
    Palmer P; Tovey MG; Raschilas F; Brassart L; Meritet JF; Porcher R; Lebon P
    Eur Cytokine Netw; 2007 Jun; 18(2):108-14. PubMed ID: 17594944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Human interferons: biological and clinical promises and premises].
    Jasmin C
    Schweiz Med Wochenschr; 1991 Mar; 121(13):463-6. PubMed ID: 1709521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.
    Damdinsuren B; Nagano H; Wada H; Kondo M; Ota H; Nakamura M; Noda T; Natsag J; Yamamoto H; Doki Y; Umeshita K; Dono K; Nakamori S; Sakon M; Monden M
    Int J Oncol; 2007 Jan; 30(1):201-8. PubMed ID: 17143530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of interferon mediated anti-viral resistance.
    Clarke CJ; Trapani JA; Johnstone RW
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):117-30. PubMed ID: 12476793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redefining the role of interferon in the treatment of malignant diseases.
    Bracarda S; Eggermont AM; Samuelsson J
    Eur J Cancer; 2010 Jan; 46(2):284-97. PubMed ID: 19906524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstitution of endogenous interferon a by recombinant interferon in hairy cell leukemia.
    Shehata M; Schwarzmeier JD; Nguyen ST; Hilgarth M; Berger R; Hubmann R; Kickmaier S; Decker T
    Cancer Res; 2000 Oct; 60(19):5420-6. PubMed ID: 11034083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic effects of interferons: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM
    Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing effectiveness of interferon-alpha for malignancies.
    Lindner DJ; Kalvakolanu DV; Borden EC
    Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-99-S9-104. PubMed ID: 9208879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferons, a class of cytokines with a large therapeutic activity range].
    Billard C
    Bull Cancer; 1993 Sep; 80(9):741-56. PubMed ID: 7515733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A peptide mimetic of human interferon (IFN)-beta.
    Sato A; Sone S
    Biochem J; 2003 Apr; 371(Pt 2):603-8. PubMed ID: 12542398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.